908 Devices (MASS) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue reached $14 million, up 16% year-over-year, with $3.1 million from the RedWave acquisition completed in April.
H1 2024 revenue was $24 million, up 11% year-over-year, with net loss widening to $23.5 million; Q2 net loss was $12.5 million.
Handheld device revenue grew 26% to $11.1 million in Q2, while desktop revenue declined 9% to $2.9 million.
Recurring revenue represented 38% of total revenue in Q2, increasing to $5.3 million, mainly from service.
Integration of RedWave completed, expanding the handheld portfolio and customer base.
Financial highlights
Gross profit for Q2 2024 was $7.4 million (53% margin), up from $5.8 million (48%) in Q2 2023; adjusted gross profit was $8.2 million (58% margin).
Operating expenses rose to $21 million in Q2 2024, including acquisition/integration costs and higher stock-based compensation.
Net loss for Q2 2024 was $12.5 million, compared to $9.3 million in Q2 2023; adjusted EBITDA loss was $7.3 million.
Cash, cash equivalents, and marketable securities totaled $77.4 million as of June 30, 2024, with no debt.
Service revenue grew 56% year-over-year in Q2 2024, with service gross margin improving by 12 percentage points.
Outlook and guidance
2024 revenue expected at $63–$65 million, up 25–29% over 2023, including $11 million from RedWave.
Core business revenue guidance reiterated at $52–$54 million (4–8% YoY growth).
Adjusted gross margin for 2024 projected in the mid-50% range, with further expansion in 2025.
Handheld revenue mix expected to increase, with desktop contribution slightly lower in H2 2024.
Existing liquidity expected to cover operating and capital needs for at least the next 12 months.
Latest events from 908 Devices
- Transformation and innovation in handheld detection devices drive strong growth and profitability.MASS
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Strong growth, innovation, and global expansion set the stage for profitability by 2027.MASS
Leerink Global Healthcare Conference 20269 Mar 2026 - Up to $100 million in securities to fund growth in handheld chemical analysis markets.MASS
Registration Filing9 Mar 2026 - Handheld detection tools, new products, and software drive growth and recurring revenue in 2026.MASS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 18% to $56.2M, margins hit 57%, and Q4 Adjusted EBITDA turned positive.MASS
Q4 20253 Mar 2026 - Handheld growth, RedWave integration, and innovation set the stage for future acceleration.MASS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - RedWave acquisition and product innovation drive growth, margin gains, and market expansion.MASS
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Q3 revenue up 17%, but net loss widened on goodwill impairment and RedWave acquisition costs.MASS
Q3 202415 Jan 2026 - Portfolio expansion, RedWave synergies, and operational changes position for growth in 2025.MASS
Stifel 2024 Healthcare Conference13 Jan 2026